When To See Mars As A ‘Cherry' On The Moon This Weekend In Rare Event
In an alignment of celestial bodies, Mars was captured here rising out of a lunar occultation on 13 ... More January 2025 using the new Visitor Center 0.6-meter Shreve Telescope at the U.S. National Science Foundation Kitt Peak National Observatory (KPNO), a Program of NSF NOIRLab, near Tucson, Arizona. KPNO/NOIRLab/NSF/AURA/J. Winsky
On Sunday, June 29, the moon and Mars reach conjunction, appearing less than 0.2 degrees apart. For most viewers, Mars will seem like a reddish 'cherry' perched above a spectacular 24%-lit waxing crescent moon.
The duo will be above the western horizon shortly after sunset and remain easily visible, if skies are clear, for about an hour.
A conjunction is an astronomical term for when two or more objects shine close together in the night sky, as seen from Earth. They are line-of-sight illusions.
From the Pacific Ocean close to northern South America, the moon will briefly occult Mars, something that was seen from North America on Jan. 13.
Sunday, June 29: Moon And Mars In Conjunction Stellarium
In a warm-up to the main event, on Saturday, June 28, the 16%-lit waxing crescent moon will appear — also above the western horizon around 45 minutes after sunset —below and to the right of Mars. In between the two will be the blue star Regulus, the brightest star in the constellation Leo, 'The Lion.' The striking trio will appear almost evenly spaced in the sky, creating a near-perfect line.
Saturday, June 28: Moon, Regulus And Mars Stellarium
Following the close conjunction, the crescent moon will continue climbing higher in the sky over the next few nights, pulling away from Mars and Regulus. By Monday, June 30, the moon will be 33%-illuminated and will still form a beautiful visual line-up with Mars and Regulus. Planetary Conjunctions Coming Soon
The next major planetary conjunctions will see Venus and Jupiter appear to be just 2.4 degrees apart before sunrise on Aug. 12 and a crescent moon and Venus just 0.8 degrees apart before sunrise on Sept. 19. Forbes In Photos: Sharpest-Ever Views Of The Sun's Surface Reveal 'Stripes' By Jamie Carter Forbes When To See June's 'Strawberry Moon,' The Lowest Full Moon Since 2006 By Jamie Carter Forbes 'Biggest Booms Since The Big Bang' Found As Black Holes Shred Stars By Jamie Carter
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Autism diagnoses occurring earlier for boys, girls often wait years, analysis finds
Autism is being diagnosed earlier in young children, especially in boys, according to a major new analysis of medical records published on Tuesday. Conducted by Epic Research -- the data and analytics arm of the electronic health record software company, Epic Systems -- the analysis also found that many girls still face years-long delays in receiving a diagnosis and an increasing share of women are not diagnosed until adulthood. This raises concerns about missed opportunities for early support, Dr. Catherine Lord, the George Tarjan Distinguished Professor of Psychiatry and Education in the David Geffen School of Medicine at UCLA, told ABC News. MORE: RFK Jr. lays out new studies on autism, shuts down 'better diagnoses' as a cause "There is evidence that girls are often diagnosed later than boys, and particularly girls with milder symptoms are missed entirely," Lord, who was not involved in the analysis, said. "When you add in adults seeking a diagnosis later in life -- often more women than men -- it pushes the average age of diagnosis for females even higher." The study reviewed records from more than 338,000 patients who received their first autism spectrum disorder diagnosis between 2015 and 2024, using aggregated electronic health record data from hospitals and clinics nationwide to study health care trends. While not peer-reviewed, Epic Research's work is vetted internally by the company's clinical and research experts. The median age at diagnosis for all children fell from age 7 in 2015 to age 6 in 2024, the analysis suggested. For boys, the median age dropped from age 7 to age 5, with nearly half diagnosed before age 5 in 2024. Girls showed no similar shift, the analysis found. Their median age of diagnosis remained at about age 8, and only about one-third were diagnosed before age 5. The disparity persisted into adulthood, with one in four women first diagnosed at age 19 or older, compared with about one in eight men, the analysis found. Although the median age for diagnosis dropped, the average age remained at about 10.5 years old, likely implying that some people were being diagnosed much later, potentially into adulthood. Early detection matters because therapies, school accommodations, and interventions -- often involving speech-language pathologists, occupational therapists and developmental pediatricians -- are most effective when started early in life, Lord explained. "The biggest time of change particularly in developing language, is in the early years," Lord said. "Interventions can speed up learning and help prevent later anxiety and depression by making life easier for autistic kids and their families." MORE: RFK Jr.'s comments on autism draw reactions from parents and experts Early signs of autism can include limited eye contact, not responding to their name, delayed speech, repetitive behaviors such as hand-flapping or lining up objects, intense or unusual interests, and distress over changes in routine, according to the Centers for Disease Control and Prevention (CDC) , In girls, these signs may be harder to notice or focused on socially typical topics, which can delay recognition. For families facing barriers to diagnosis, Lord recommended seeking evaluations through schools, contacting state-run early intervention programs for children under age three. She also recommended relying on credible sources such as the CDC, Autism Speaks and the Autism Science Foundation for more information. "There's much more hope now for autism," she said. "Not to 'cure' it, but to support people, figure out their strengths, and help them find their place in the world." Christian S. Monsalve, MD is a functional psychiatry fellow and a member of the ABC News Medical Unit. Solve the daily Crossword
CNET
an hour ago
- CNET
Here's How to Spot Bright Fireballs During the Dazzling Perseids Meteor Shower
Skygazers rejoice, the summer isn't finished with delivering dazzling meteor showers. The last week of July saw dueling meteor showers taking over the sky, but the most popular meteor shower of the year won't hit its peak until next week. The Perseids meteor shower is about to give you a real light show, provided you're far enough away from light pollution to see it. Perseids are known for their bright fireballs and plentiful meteors. The show started on July 17, and will run through Aug. 23. The reason the Perseids meteor shower is so popular is twofold. First, it takes place in the summer, so going outside and watching it is less uncomfortable than other large meteor showers like Quadrantids, which takes place in wintery January. The other reason is that it's one of the most active meteor showers of the year. During its peak, the meteor shower is known to rain down as many as 100 meteors per hour, according to the American Meteor Society. These not only include your typical shooting stars, but also a higher chance for fireballs, which are meteors that explode as they enter orbit. Per NASA, fireballs tend to last longer than standard shooting stars and can come in a variety of different colors. Perseids come to Earth courtesy of the 109P/Swift-Tuttle comet. Earth's orbit around the sun brings it through Swift-Tuttle's tail every year. The comet itself takes 133 years to orbit the sun. Its last perihelion -- the point at which it's the closest to the sun -- was in 1992. It won't be back until the year 2125. Until then, it leaves behind an excellent tail of dust and debris to feed us yearly meteor showers. How to catch the Perseids meteor shower The best time to view the Perseids is during its peak, which occurs on the evenings of Aug. 12 and 13. During this time, the shower will produce anywhere from 25 to 100 meteors per hour on average. However, since the shower officially lasts for over a month, you have a chance to see a shooting star on any given evening, provided that you're far enough away from light pollution. Thus, if you're planning on watching this year's Perseids during their peak, you'll want to get out of the city and suburbs as far as possible. According to Bill Cooke, lead of NASA's Meteoroid Environments Office, folks in the city might see one or two meteors from the meteor shower per hour, which is pocket change compared to what those outside city limits might see. Regardless, once you've arrived at wherever you want to watch the meteors, you'll want to direct your attention to the radiant, or the point at which the meteors will appear to originate. Like all meteors, Perseids are named after the constellation from which they appear. In this case, it's Perseus. Per Stellarium's free sky map, Perseus will rise from the northeastern horizon across the continental US on the evenings of Aug. 12 and 13. It'll then rise into the eastern sky, where it'll remain until after sunrise. So, in short, point yourself due east and you should be OK. Binoculars may help, but we recommend against telescopes since they'll restrict your view of the sky to a very small portion, which may hinder your meteor-sighting efforts. The American Meteor Society also notes that the moon may give viewers some difficulty. Perseids' peak occurs just three days after August's full moon, so the moon will still be mostly full. Thus, it is highly probable that light pollution from the moon may reduce the number of visible meteors by a hefty margin, depending on how things go.
Medscape
2 hours ago
- Medscape
Does This Side Effect Spell Doom for the GLP-1's?
This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. About a year ago, I was talking to one of my friends about the slew of studies showing very broad benefits of the GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Mounjaro). including weight loss and improved diabetes control. But studies also showed improved heart and kidney health, as well as lower overall mortality. Some analyses found reductions in problem drinking, smoking, and even compulsive shopping among people taking these drugs. I told my friend that I thought these drugs were complete game changers, fundamentally 'anticonsumption' agents that are the cure for society's primary ill of overconsumption. 'Yeah, but what about the side effects?' he said. I said, 'Sure, some gastrointestinal issues can come up, but usually it's not that bad.' Still, I demurred, 'It's early days; perhaps after 10 years on the drugs your eyes fall out or something.' This week's study doesn't suggest that GLP-1's cause your eyes to fall out exactly, but, as you'll see in a second, it's not that far off. We're talking about this study, ' Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes,' appearing in JAMA Network Open , which looks at eye problems in people taking the two most potent GLP-1 drugs. This was a huge retrospective cohort study using the TrinetX database, which contains electronic health record data on millions of patients across the United States. Researchers identified more than a million individuals with diabetes in the database who had no history of eye disease. They then identified when they were first prescribed Ozempic, Mounjaro, or a bunch of non-GLP-1 diabetes medications (such as insulin and metformin) which serve as controls here. They were on the lookout for conditions that some smaller studies had suggested might be associated with the weight-loss drugs: disorders of the optic nerve — in particular, a rather rare condition that can occur even outside diabetes, known as non-arteritic anterior ischemic optic neuropathy (NAION). This is a syndrome caused by a decline in blood supply to the optic nerve and is characterized by the sudden and painless loss of eyesight in one eye, which can lead to permanent blindness. It seems straightforward to ask which group — those who got the GLP-1 drugs or those who took other diabetes drugs — had more eye problems. But you probably suspect that these two groups weren't exactly comparable even before they started the drug. People who took weight-loss drugs were younger, more likely to be female, more likely to be on antihypertensive drugs, more likely to have a history of sleep apnea, and much more likely to have obesity. This is a classic apples-vs-oranges problem in observational research, one that was overcome, in this case, through a form of statistical wizardry called propensity score matching. In this process, each patient is assigned a likelihood of being prescribed the weight-loss drug, and then they are matched with someone with similar propensities. Thus, only one of each pair actually received the drug. Naturally, not everyone was matched; the apples and oranges that were just too appley or orangey were dropped from further analysis. After matching, the two groups were much more similar. Now that we have two similar groups — one of orangish apples and the other of appley oranges — we can compare the rates of NAION between them. Of 79,699 individuals started on either Ozempic or Mounjaro, 35 developed NAION within 2 years of follow-up. Of 79,699 started on non-GLP-1 diabetes drugs, 19 developed NAION over a similar duration of follow-up. That's 0.04% compared with 0.02%. There are a couple of ways to look at the data. On the relative scale, we see nearly a doubling of the risk for this eyesight-threatening disorder among people taking GLP-1 drugs. But on the absolute scale, any given individual's chance of actually getting this disorder is vanishingly small; the rate in the GLP-1 group was 462 per million individuals, compared with a baseline rate of about 238 per million individuals. Identifying rare risks like this is still important, especially for drugs that are as widely prescribed as the GLP-1's. Patients and providers need to have this in the back of their minds so that, if an unusual eye symptom does develop, everyone can react quickly. It's still not clear how these drugs could lead to NAION. It's true that the optic nerve has GLP-1 receptors on it, so this could be a direct drug effect. But the researchers suggest other possibilities as well, including the idea that sudden metabolic changes associated with weight loss or glucose effects from the drugs may change the microenvironment of the eye. I hate to fall back on 'more research is necessary,' but the truth is, more research is necessary to figure out how this works and, importantly, who is most at risk. I should remind you that this study shows us correlation, not causation. Even with propensity score matching, there will still be differences between the comparison groups that aren't fully accounted for. Beyond that, the very fact that people may be on alert for eye disorders among those taking GLP-1's may become something of a self-fulfilling prophecy in a study like this. If physicians are primed to think of a rare diagnosis like NAION when they see a patient on a GLP-1 drug, they might be more likely to make the diagnosis than they would if presented with exactly the same symptoms in someone not taking the drug. When the outcome is rare like this, minor biases can drive the results. So, I'm not ready to go back on my statement that these drugs are game changers. They clearly are. But we'd be naive to assume that there wouldn't be some risk. I'm encouraged that this particular risk is not nearly of a magnitude and frequency to counteract the obvious benefits of the drugs. In the end, this is one of those knowledge-is-power things. I don't think we'll see enthusiasm dampen for the GLP-1 drugs because of NAION, but it doesn't hurt for any of us — patients or providers — to be aware of it.
